The 8th Annual CKD Drug Development Summit, Boston

Published on 17/03/2026

March 17-18, 2026
Boston, USA

ENYO Pharma will attend the 8th Chronic Kidney Disease Drug Development Summit, March 17โ€“18 in Boston. This industry-led event is dedicated to advancing preventive and regenerative therapies that target kidney disease effectively, and to exploring opportunities for label expansion in rare renal disorders.
Jacky Vonderscher, our CEO and co-founder, will present โ€œ๐€ ๐๐จ๐ฏ๐ž๐ฅ ๐๐จ๐ญ๐ž๐ง๐ญ๐ข๐š๐ฅ ๐“๐ก๐ž๐ซ๐š๐ฉ๐ฒ ๐Ÿ๐จ๐ซ ๐€๐ฅ๐ฉ๐จ๐ซ๐ญ ๐’๐ฒ๐ง๐๐ซ๐จ๐ฆ๐ž ๐ฐ๐ข๐ญ๐ก ๐€๐ฉ๐ฉ๐ฅ๐ข๐œ๐š๐›๐ข๐ฅ๐ข๐ญ๐ฒ ๐ข๐ง ๐Œ๐ฎ๐ฅ๐ญ๐ข๐ฉ๐ฅ๐ž ๐‘๐š๐ซ๐ž & ๐‚๐จ๐ฆ๐ฆ๐จ๐ง ๐‘๐ž๐ง๐š๐ฅ ๐ƒ๐ข๐ฌ๐ž๐š๐ฌ๐ž๐ฌโ€ on Day 1, March 17th at 2:30-3:00 pm. He will discuss ENYO Pharmaโ€™s renal programs with a focus on our ๐๐ก๐š๐ฌ๐ž 2 ๐€๐‹๐๐„๐’๐“๐‘๐ˆ๐€-1 ๐œ๐ฅ๐ข๐ง๐ข๐œ๐š๐ฅ ๐ฌ๐ญ๐ฎ๐๐ฒ with Vonafexor that lately demonstrated ๐ฌ๐ข๐ ๐ง๐ข๐Ÿ๐ข๐œ๐š๐ง๐ญ๐ฅ๐ฒ ๐ซ๐ž๐๐ฎ๐œ๐ž๐ ๐š๐ฅ๐›๐ฎ๐ฆ๐ข๐ง๐ฎ๐ซ๐ข๐š ๐š๐ง๐ ๐ซ๐ž๐ฏ๐ž๐ซ๐ฌ๐ž๐ ๐ญ๐ก๐ž ๐ž๐ฑ๐ฉ๐ž๐œ๐ญ๐ž๐ ๐๐ž๐œ๐ฅ๐ข๐ง๐ž ๐ข๐ง ๐ค๐ข๐๐ง๐ž๐ฒ ๐Ÿ๐ฎ๐ง๐œ๐ญ๐ข๐จ๐ง with durable effects after treatment discontinuation in Alport syndrome.

https://ckd3-summit.com/

Read next in 'Events'

News

Latest Press Release

ENYO Pharma appoints Jeff George as Chairman to support next phase to growth and Phase 3 readiness.
Leadership transition reinforces ENYOโ€™s strategic positioning following pos...

> Read more